Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment
Overview
Authors
Affiliations
The chronic lymphocytic leukemia (CLL) niche is a closed environment where leukemic cells derive growth and survival signals through their interaction with macrophages and T lymphocytes. Here, we show that the CLL lymph node niche is characterized by overexpression and activation of HIF-1α, which increases adenosine generation and signaling, affecting tumor and host cellular responses. Hypoxia in CLL lymphocytes modifies central metabolic pathways, protects against drug-driven apoptosis, and induces interleukin 10 (IL-10) production. In myeloid cells, it forces monocyte differentiation to macrophages expressing IRF4, IDO, CD163, and CD206, hallmarks of the M2 phenotype, which promotes tumor progression. It also induces IL-6 production and enhances nurturing properties. Low oxygen levels decrease T-cell proliferation, promote glycolysis, and cause the appearance of a population of PD-1 and IL-10-secreting T cells. Blockade of the A2A adenosine receptor counteracts these effects on all cell populations, making leukemic cells more susceptible to pharmacological agents while restoring immune competence and T-cell proliferation. Together, these results indicate that adenosine signaling through the A2A receptor mediates part of the effects of hypoxia. They also suggest that therapeutic strategies to inhibit the adenosinergic axis may be useful adjuncts to chemotherapy or tyrosine kinase inhibitors in the treatment of CLL patients.
Aoki T, Wong V, Yin T, Nakamura E, Endo Y, Hayashida K Front Immunol. 2024; 15:1362858.
PMID: 38545102 PMC: 10967020. DOI: 10.3389/fimmu.2024.1362858.
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.
Sanchez Suarez M, Roldan A, Alarcon-Payer C, Rodriguez-Gil M, Poquet-Jornet J, Puerta Puerta J Pharmaceutics. 2024; 16(1).
PMID: 38258066 PMC: 10818903. DOI: 10.3390/pharmaceutics16010055.
Unraveling the Bone Tissue Microenvironment in Chronic Lymphocytic Leukemia.
Giannoni P, Marini C, Cutrona G, Sambuceti G, Fais F, de Totero D Cancers (Basel). 2023; 15(20).
PMID: 37894425 PMC: 10605026. DOI: 10.3390/cancers15205058.
Progress of research on PD-1/PD-L1 in leukemia.
Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y Front Immunol. 2023; 14:1265299.
PMID: 37822924 PMC: 10562551. DOI: 10.3389/fimmu.2023.1265299.
HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies.
Zhao Y, Xing C, Deng Y, Ye C, Peng H Genes Dis. 2023; 11(1):234-251.
PMID: 37588219 PMC: 10425810. DOI: 10.1016/j.gendis.2023.02.039.